Pi Cardia
Pi-Cardia is a medical device company based in Israel, focused on developing innovative, non-implant, catheter-based solutions for structural heart diseases. The company specializes in treating conditions like heart valve calcification and aortic stenosis. Pi-Cardia aims to provide safe, effective, and affordable treatments, offering alternatives to traditional implant-based methods. The company's product lineup includes the Leaflex Performer, a next-generation aortic repair solution, and the ShortCut Device, which is the first dedicated leaflet splitting solution. The ShortCut device has received FDA Breakthrough Device Designation and market clearance, highlighting its safety and efficacy as demonstrated in clinical studies. Pi-Cardia's solutions are designed for use by healthcare providers and medical professionals treating patients with structural heart diseases. Led by CEO Erez Golan, Pi-Cardia is expanding its global commercialization efforts under the guidance of Gary Gratson. The company has achieved significant regulatory milestones and is supported by investors, including Sofinnova Partners, a venture capital firm specializing in life sciences and medical technology.
Work at Pi Cardia in HR or recruiting? Claim this page
Headcount trend
Pi Cardia went from 41 employees in Jul 2023 to 55 in Jun 2025. Jan to Jun 2025: 6 people joined, 4 left.
Headcount data through Jun 2025
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Apr 2020 | Venture | $27M | 1 | |
| Jan 2016 | Series C | $10M | 3 |
Org structure
Headcount by department
Peer reviews
Worked with someone at Pi Cardia?
Anonymous peer reviews on OffTheRecord
Similar companies
Pi Cardia FAQ
How many employees does Pi Cardia have?
Pi Cardia has about 55 employees, up 1.9% over the 3 months to Jun 2025.
What is Pi Cardia's revenue per employee?
Pi Cardia makes about $53K in revenue per employee, based on $2.9M annual revenue and 55 employees.
How much funding has Pi Cardia raised?
Pi Cardia has raised $37M in total funding.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.